Entelos Acquires Iconix in $14.1M Deal | GenomeWeb
Entelos yesterday said that it has acquired toxigenomics firm Iconix Biosciences in an all-share transaction initially valued at $14.1 million but with the potential of rising to $39 million.
 
Foster City, Calif.-based Entelos said that it would issue up to 12,776,658 shares of its stock to Iconix shareholders and a potential maximum earn-out payment of $25 million if certain milestones are achieved within one year following the close of the deal today. The deferred consideration also would be paid in Entelos shares.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.